Evaluating a novel lung cancer treatment with BALB/c mice
A fully-integrated biopharmaceutical company is developing an innovative aerosolized immunotherapeutic for the devastating disease of lung cancer.
A comprehensive study by researchers was recently published and outlines the preclinical pharmacological data for DV281, their inhaled aerosolized immunotherapeutic agent.
A series of in vitro and in vivo studies were conducted in primary cells, mice, and cynomolgus monkeys to support the development of DV281 for lung cancer therapy.
Complete the form to the right to access our case study, which highlights the preclinical data for this novel immunotherapeutic agent and how BALB/c mice were utilized to assess its effects.
